Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer

Clinical Nuclear Medicine

Volumn 37, Issue 7, 2012, Pages 637-643

  Jadvar, Hossein ^a   Desai, Bhushan ^a   Ji, Lingyun ^a   Conti, Peter S ^a   Dorff, Tanya B ^a   Groshen, Susan G ^a   Gross, Mitchell E ^a   Pinski, Jacek K ^a   Quinn, David I ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

18F FDG; 18F NaF; cancer; prostate; PSA

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; SODIUM FLUORIDE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MALE; METASTASIS; OCCULT METASTATIC DISEASE; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RANK SUM TEST;

FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SODIUM FLUORIDE; WHOLE BODY IMAGING;

EID: 84862554668     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318252d829     Document Type: Article

References (23)

1. National Cancer Institute. SEER: The Surveillance, Epidemiology, and End Results ProgramVbased within the Surveillance Research Program at the National Cancer Institute. Baltimore, MD: National Cancer Institute. Available at: Http://seer.cancer.gov.
2. Dong JT, Rinker-Schaeffer CW, Ichikawa T, et al. Prostate cancerVbiology of metastasis and its clinical implications. World J Urol. 1996;14:182-189.
3. Haseman MK, Rosenthal SA, Polascik TJ. Capromab pendetide imaging of prostate cancer. Cancer Biother Radiopharm. 2000;15:131-140.
4. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031-2041.
5. Gillies RJ, Robey I, Catenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49:24SY42S.
6. Jadvar H. Molecular imaging of prostate cancer with [F-18]- fluorodeoxyglucose PET. Nat Rev Urol. 2009;6:317-323.
7. Iagaru A, Mittra E, Dick DW, et al. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252-259.
8. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-297.
9. Centers for Medicare & Medicaid Services. CMS Manual. Pub 100-03 Medicare National Coverage Determinations. Baltimore, MD: Centers for Medicare & Medicaid Services. Available at: Http://www.cms.gov/transmittals/ downloads/R119NCD.pdf.
10. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-545.
11. Roach III M, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
12. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical TrialsWorking Group. J Clin Oncol. 2008;26:1148-1159.
13. Segall G, Delbeke D, Stabin MG, et al. SNM guideline for sodium 18F-fluoride PET/CT bone scan 1.0. J Nucl Med. 2010;51:1813-1820.
14. Bracarda S, Logothetis C, Sternberg CN, et al. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int. 2011; 107(suppl 2):13-20.
15. Carroll P. Rising PSA after a radical treatment. Eur Urol. 2001;40:9-16.
16. Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patienst with prostatespecific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51-60.
17. Schöder H, Herrmann K, Gönen M, et al. 2-[18F]fluoro-2- deoxyglucose positron emission tomography for detection of disease in patients with prostatespecific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11: 4761-4769.
18. Chang CH, Wu HC, Tsai JJ, et al. Detecting metastatic pelvic lymph nodes by (18)F-2-deoxyglucose positron emission tomography in patients with prostatespecific antigen relapse after treatment for localized prostate cancer. Urol Int. 2003;70:311-315.
19. Gomez P, Manoharan M, Kim SS, et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: When is it indicated? BJU Int. 2004;94:299-302.
20. Cook GJR, Venkitaraman R, Sohaib AS, et al. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging. 2011;38:7-13.
21. Iagaru A, Mittra E, Yaghoubi S, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: Results of the pilotphase study. J Nucl Med. 2009;50:501-505.
22. Wade AA, Scott JA, Kuter I, et al. Flare response in 18F-fluoride ion PET bone scanning. AJR Am J Roentgenol. 2006;186:1783-1786.
23. Basu S, Rao R, Bailey DL. Combined 18F-FDG and fluoride approach in PET/CT imaging: Is there a clinical future? [letter]. J Nucl Med. 2010;51:165-167.